Company’s Technology Highlighted in Eleven Paper Presentations and One Electronic Poster

LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced a total of 12 abstracts highlighting LENSAR’s technology have been accepted for presentation at the 2021 Annual Meeting of the American Society of Cataract and Refractive Surgeons, being held July 23-27, 2021 in Las Vegas, NV.

In addition to these presentations, the Company will be hosting in-person demonstrations of its next-generation ALLY™ Adaptive Cataract Treatment System. LENSAR expects to submit a 510(k) application for regulatory clearance of ALLY in the first quarter of 2022, with a commercial launch planned for later in 2022.

“ASCRS this year represents several highly anticipated milestones for LENSAR. We have a significant number of accepted paper presentations in the scientific program that will highlight clinical data demonstrating the effectiveness of our laser systems. The wide range of topics covered in these presentations is continuing validation of LENSAR’s femtosecond laser technology, its versatility and the significant benefits of its use in cataract surgery, as well as its ability to empower surgeons to deliver improved patient outcomes. We are also extremely excited to present ALLY, the next generation, fully integrated femtosecond laser and phacoemulsification platform during the congress,” said Nick Curtis, Chief Executive Officer. “This will be the very first time surgeons will have hands-on access to the ALLY Adaptive Cataract Surgery System at a major congress. The response from our surgeon advisory board has been tremendous and we are excited to share this opportunity with the broader ophthalmic community.”

Mr. Curtis added, “LENSAR continues to lead the industry in femtosecond laser cataract surgery innovation. We are extremely grateful to our partner surgeon practices for their continued support and user feedback that allow us to continually improve our laser systems. We are committed to delivering meaningful improvement and disruptive technology in this space.”

Details on the paper and poster presentations follow. For additional information on LENSAR-hosted events during the ASCRS Annual Meeting, or to request an ALLY demonstration, please contact Lauren Gyoerkoe at lauren.gyoerkoe@lensar.com.

SATURDAY, JULY 24, 2021

Session Title: Management of High Astigmatism Combined Femto Arcuate Keratotomy & Toric IOL Implantation Using ORA in Patients Undergoing Cataract Surgery

Session: Femtosecond Laser-Assisted Cataract Surgery

Presenter: P. Dee G. Stephenson, MD, FACS, ABO, FACS

Location: MBCR - Level 2, Surf CD

Time: 3:45pm – 3:50pm

Session Title: Outcomes of Toric IOL Implantation Guided by Iris Registration-Guided Capsular Marks and Evaluation of Postoperative IOL Rotation

Session: Femtosecond Laser-Assisted Cataract Surgery

Presenter: Denise M. Visco, MD, MBA, ABO

Location: MBCR - Level 2, Surf CD

Time: 4:00pm – 4:05pm

Session Title: Optimization of Femtosecond Laser and Phacoemulsification Parameters with Automated Cataract Density Grading

Session: Femtosecond Laser-Assisted Cataract Surgery

Presenter: Gabriel Quesada, MD

Authors: John A. Vukich, MD, Kevin L. Waltz, MD, OD, Rodrigo A. Quesada, MD

Location: MBCR - Level 2, Surf CD

Time: 4:10pm – 4:15pm

Session Title: Comparison of Toric IOL Refractive Outcomes Using Digital Markerless System Versus Topography-Guided, Capsular Plane Alignment Marking

Session: Femtosecond Laser-Assisted Cataract Surgery

Presenter: Harvey S. Uy, MD

Authors: Jose Tecson III, MD

Location: MBCR - Level 2, Surf CD

Time: 4:50pm – 4:55pm

Session Title: Endothelial Protection Using Capsulotomy Buttons Among Eyes with Fuchs Endothelial Dystrophy Undergoing Laser-Assisted Cataract Surgery

Session: Femtosecond Laser-Assisted Cataract Surgery

Presenter: Harvey S. Uy, MD

Location: MBCR - Level 2, Surf CD

Time: 4:55pm – 5:02pm

SUNDAY, JULY 25, 2021

Session Title: Comparative Evaluation of High Vacuum Manual Phacoemulsification and Femtosecond Laser Assisted Cataract Surgery

Session: Surgical Comparisons

Presenter: Robert J. Weinstock, MD

Authors: Vasilios F. Diakonis, PhD, MD, Kirkland Castellano, MD

Location: MBCR - Level 2, Surf CD

Time: 8:00am – 8:05am

Session Title: Comparison of Enhancement Rates Following Image Guided Iris Registration Versus Intraoperative Aberrometry for Toric IOL Alignment

Session: Astigmatism Management and Toric IOL Alignment

Presenter: Michael G Orr, MD, ABO

Location: MBCR - Level 2, Surf AB

Time: 10:15am – 10:20am

Session Title: Refractive Outcomes of Toric IOL Alignment Using Femtosecond Laser Image Guided Iris Registration and Comparison with Published Literature

Session: Astigmatism Management and Toric IOL Alignment

Presenter: Denise M. Visco, MD, MBA, ABO

Location: MBCR - Level 2, Surf AB

Time: 10:30am – 10:35am

MONDAY, JULY 26, 2021

Session Title: Effectiveness of Femtosecond Laser Assisted Cataract Surgery Astigmatism Correction with Iris Registration for Low Power Toric IOL Alignment

Session: Presbyopia Correcting IOLs- Trifocal IOLs II

Presenter: Gregory D. Parkhurst, FACS, MD

Authors: Brett H Mueller II, DO, PhD

Location: MBCR - Level 2, Surf EF

Time: 10:10am – 10:15am

Session Title: Safety and Effectiveness of High Vacuum Occlusion Phaco with Flow Control Surge Prevention

Session: Cataract Surgery II

Presenter: Jonathan D. Solomon, MD

Location: MBCR - Level 2, Surf CD

Time: 10:42am – 10:47am

Session Title: Mission Cataract: Femtosecond Laser Assisted Cataract Surgery in Difficult and Challenging Cases

Session: Challenging Cases

Presenter: William L. Soscia, MD

Authors: William J. Lahners, MD, Joshua W. Kim, MD, Joaquin De Rojas, MD

Location: MBCR - Level 2, Surf CD

Time: 4:00pm – 4:05pm

ELECTRONIC POSTER

Session Title: Clinical Outcomes of Femtosecond Laser Arcuate Incisions in the Management of Low Corneal Astigmatism Using a Novel Arcuate Incision Formula

Session: Cataract Posters (On-Demand)

Presenter: Preeya K. Gupta, MD

Authors: Richard S. Davidson, MD, ABO, Nicole R. Fram, MD, ABO, Jonathan D. Solomon, MD, Gregory D Parkhurst, MD, FACS, Nandini Venkateswaran, MD, Gary N. Wortz, MD, ABO

Location: ON DEMAND

About LENSAR

LENSAR is a commercial-stage medical device company focused on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining better visual outcomes, efficiency and reproducibility by providing advanced imaging, simplified procedure planning, efficient design and precision.

Forward-looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company’s development timeline and the future market potential of ALLY. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “estimate,” “target,” “mission,” “may,” “will,” “would,” “should,” “could,” “target,” “potential,” “project,” “predict,” “contemplate,” “potential,” or the negative thereof and similar words and expressions.

Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Important factors that could impair the value of the Company’s assets or business are disclosed under the heading “Risk Factors” contained in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021, filed with the Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in its other filings with the SEC, each accessible on the SEC’s website at www.sec.gov and the Investor Relations section of the Company’s website at https://ir.lensar.com. All forward-looking statements are expressly qualified in their entirety by such factors. Except as required by law, the Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. These forward-looking statements should not be relied upon as representing LENSAR’s views as of any date subsequent to the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210715005322/en/